Search | Clinical Trials Finder

Conditions: Osteoarthritis of the Knee
Interventions: TV-45070, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 42
States / cities: Anaheim, California • Cerritos, California • El Cajon, California + 35 more

Conditions: Barrett Esophagus, Esophageal Adenocarcinoma
Interventions: Aspirin, Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 9
States / cities: Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more

Conditions: Thrombosis
Interventions: BMS-986141, Aspirin, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 27
States / cities: Phoenix, Arizona • Newport Beach, California • Newark, Delaware + 21 more

Conditions: Arthritis
Interventions: Tesla BioHealing(R) Biophoton Generators; Device
Lead sponsor: First Institute of All Medicines; Other
Eligibility: 18 Years to 80 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Butler, Pennsylvania

Conditions: Birth, Spontaneous Abortion
Interventions: acetylsalicylic-acid (aspirin), Folic acid; Drug · Dietary Supplement
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 1,228 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 4
States / cities: Denver, Colorado • Buffalo, New York • Scranton, Pennsylvania + 1 more

Conditions: Pre-Eclampsia, Pregnancy Loss
Interventions: Aspirin 162 mg, Aspirin 81mg; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dyslipidemia
Interventions: niacin extended-release (NER), aspirin (ASA), aspirin placebo (ASA Pbo); Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 26
States / cities: Huntsville, Alabama • Scottsdale, Arizona • Tucson, Arizona + 22 more

Conditions: Pharyngitis
Interventions: Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo, Acetaminophen + placebo, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Healthy
Interventions: Aspirin ingestion followed by doing a Bleeding Volume Test, Gatorade Placebo followed by Bleeding Volume Test.; Drug · Procedure
Lead sponsor: Klein, Jeffrey A., M.D.; Individual
Eligibility: 18 Years to 89 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Newport Beach, California • San Juan Capistrano, California

Conditions: Healthy Subjects
Interventions: Acetylsalicyclic acid (Fast release Aspirin, BAY1019036), Acetaminophen (Tylenol extra strength), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 16 Years to 45 Years
Enrollment: 510 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Endometriosis
Interventions: Aspirin, Placebo; Drug · Other
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Glioblastoma
Interventions: Aspirin, Placebo; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Volunteer
Interventions: aleglitazar, aspirin, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Coronary Artery Disease
Interventions: Omacor, omega-3 fatty acids in CAD patients; Drug
Lead sponsor: HeartDrug Research LLC; Other
Eligibility: 50 Years to 60 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Towson, Maryland

Conditions: Osteoarthritis, Hip
Interventions: Periarticular injection (Deep injection), Periarticular injection (Superficial injection), Bupivacaine, Placebo; Procedure · Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 50 Years to 75 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiovascular Disease
Interventions: AZD3366, Placebo, Ticagrelor, acetylsalicylic acid (ASA); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Herpes Simplex
Interventions: valacyclovir hydrochloride, placebo, valacyclovir plus aspirin; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 20 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: New Orleans, Louisiana

Conditions: Anesthesia, Surgical Procedures, Elective
Interventions: Dexmedetomidine, Placebo; Drug
Lead sponsor: Hospira, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 27
States / cities: Birmingham, Alabama • Loma Linda, California • Miami, Florida + 18 more

Conditions: Healthy
Interventions: Ticagrelor Oral Tablet - Pre-Treatment, Aspirin (ASA) Oral Tablet - Pre-Treatment, Bentracimab (PB2452) Infusion, Placebo (0.9% Sodium chloride) infusion; Drug
Lead sponsor: SFJ Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 207 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 13
States / cities: Rogers, Arkansas • Cypress, California • San Diego, California + 9 more

Conditions: Stroke, Secondary Prevention
Interventions: optional ASA as comedication, placebo to ASA, placebo to optional ASA as comedication, placebo to dabigatran etexilate, ASA 100 mg, dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 150 Years
Enrollment: 5,390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 110
States / cities: Phoenix, Arizona • Beverly Hills, California • El Cajon, California + 94 more

Conditions: Coronary Disease
Interventions: RUC-4 Compound; Drug
Lead sponsor: CeleCor Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypertension, Pulmonary
Interventions: Simvastatin, Aspirin, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more

Conditions: Impaired Glucose Tolerance, Prediabetic State
Interventions: Aspirin, Alpha lipoic acid, Olmesartan, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Hypercholesterolemia, Flushing
Interventions: Apple pectin, Aspirin 325 mg, Placebo; Other · Drug
Lead sponsor: Patrick Moriarty, MD, FACP, FACC; Other
Eligibility: 21 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Kansas City, Kansas

Search by objective public record fields.

A Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (Ointment) in Participants With Primary Osteoarthritis (OA) Affecting a Single Knee

Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

Impact of Biophoton Therapy on Chronic Severe Arthritis Pain

The Effects of Aspirin in Gestation and Reproduction

APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia

Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia

Evaluate the Time of Pain Relief of Fast Acting Aspirin Versus Acetaminophen in Subjects Diagnosed With Sore Throat Pain

In-Vivo Bleeding Volume Test for Platelet-Aspirin Interaction

Evaluate Onset of Action of a Fast Release Aspirin

Thromboxane Function in Women With Endometriosis

Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma

A Study of Aleglitazar in Combination With Aspirin in Healthy Volunteers

Effects of Omega-3 Fatty Acids on Platelets in Patients With Coronary Artery Disease With Hypertriglyceridemia

Minimal Opioid Use After Total Hip Replacement (THR)

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects

30-Day Trial of Oral Valtrex or Valtrex Plus Aspirin on Shedding of HSV DNA in Tears and Saliva of Volunteers

A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation During Monitored Anesthesia Care (MAC)

Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4

A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension

Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance

Alternative Options to Minimize Niacin-Induced Flushing